Navigation Links
Vion Pharmaceuticals to Present at 20th Annual Bear Stearns Healthcare Conference
Date:9/10/2007

is news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Annual Report on Form 10-K for the year ended December 31, 2006 and the Company's Form 10-Q for the quarter ended June 30, 2007. In particular, there can be no assurance as to the results of any of the Company's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

COMPANY CONTACT: Vion Pharmaceuticals, Inc.

Alan Kessman, Chief Executive Officer

Howard B. Johnson, President & CFO

(203)498-4210


'/>"/>
SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 A ... the NCATS rare-diseases portfolio " in Science ... new financing technique to reduce the risk associated ... and potentially unlock new levels of funding for ... product of a unique collaboration between scientists at ...
(Date:2/27/2015)... 2015 Bionomics Limited (ASX:BNO, ADR:BMICY) is to ... BNC105 in patients with metastatic renal cancer at the ... . The data will be presented by Dr. ... Comprehensive Cancer Center in California ... data identifies Ferritin and IL-8 as two baseline biomarkers ...
(Date:2/27/2015)...  Steep Hill, the industry leader in cannabis testing ... open a full service medical cannabis quality assurance laboratory ... advanced scientific tools and methodology to the state, for ... currently the only laboratory licensed by the New Mexico ... in order to meet the recently adopted regulatory requirements ...
(Date:2/26/2015)... 26, 2015  23andMe, the leading personal genetics company, ... as Privacy Officer and Corporate Counsel. Black brings a ... as well as health care regulations. As a member ... responsible for reviewing, updating and enhancing the company,s privacy ... abroad. She joined the company January 5, 2015 and ...
Breaking Biology Technology:New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 223andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2
... MUNDELEIN, Ill., April 22 Sysmex America, ... Medical Center,s (Canton, OH),beta studies for its ... solution, which combines the Sysmex HST-N hematology,automation ... II TURBO,Link, enables on-demand, automated diabetes testing ...
... Full Control of Belinostat, Consolidating ... Global Rights for the Product TopoTarget Acquires ... - Deal Covers a Payment of USD 26 million (DKK 122.8 ... - Webcast Conference Call to be Held 2pm CET, TopoTarget ...
... DC A new analysis by the Project ... are investing nearly twice as much as the ... potential risks of nanotechnology. The analysis also highlights ... risk-research investment figures for the U.S. , ...
Cached Biology Technology:Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution 2Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution 3Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution 4TopoTarget Successfully Buys Back Full Control of Belinostat 2TopoTarget Successfully Buys Back Full Control of Belinostat 3TopoTarget Successfully Buys Back Full Control of Belinostat 4TopoTarget Successfully Buys Back Full Control of Belinostat 5TopoTarget Successfully Buys Back Full Control of Belinostat 6TopoTarget Successfully Buys Back Full Control of Belinostat 7Europe spends nearly twice as much as US on nanotech risk research 2
(Date:2/5/2015)... Jan. 27, 2015   Marvin Test ... deployed, innovative test solutions for military, aerospace, ... of its TS-323 GENASYS Test Platform ... (LMSSC). GENASYS is a high-performance PXI-based system ... applications that require performance functional testing. GENASYS ...
(Date:2/5/2015)... 30, 2015  It is gratifying to see that ... for genomic science as a means to better understand ... treatment.  I was honored to participate in today,s White ... program. Since the 1980s my teams ... the first sequenced genome of a free living organism, ...
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading ... the launch of its new website design. "When ... its infancy", says Peter O,Neill , founder and CEO ... the industry needs involvement from the key players on a ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is establishing eight ... Senate during its 2013 March meeting in Bonn. The ... current and pressing issues in their research areas and ... DFG Research Units, the new units will be interdisciplinary ...
... humanity,s greatest achievements but scientists have found that working together ... chimpanzees. A series of trials by scientists found that ... understand the need to help a partner perform their role ... given tools to get grapes out of a box. They ...
... is a known risk factor for back pain and ... the 2013 Annual Meeting of the American Academy of ... related pain in 6,779 patients undergoing treatment for spinal ... Information on each patient,s age, gender, weight, smoking history, ...
Cached Biology News:DFG establishes 8 new research units 2DFG establishes 8 new research units 3DFG establishes 8 new research units 4DFG establishes 8 new research units 5Origins of human teamwork found in chimpanzees 2Origins of human teamwork found in chimpanzees 3
... Continuous flow of media and other fluid ... lab space, The speed of each individual ... flow set points, are exactly maintained. ... with variable tube types, which allows flow ...
...
... Application: Pyronin Y is most ... green to selectively and differentially stain ... In a dichromatic dye solution, Pyronin ... green stains DNA green. ...
... designed for the fast and simple integration ... any position (for the generation of transgenic ... designed to allow neomycin / kanamycin selection ... a prokaryotic promoter (gb2) for expression of ...
Biology Products: